Home › Keratoconus › NCT07841470

Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia

Corneal Crosslinking for Treatment of Progressive Keratoconus or Ectasia: Randomized Comparison of Pulsed vs. Non-pulsed Treatment

Who can join

Ages 10 to 90 · All sexes

Inclusion Criteria:

* Diagnosis of keratoconus or corneal ectasia
* Provision of written informed consent

Exclusion Criteria:

* Previous ocular condition in the study eye that may predispose for future complications including history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)
* Clinically significant corneal scarring in the proposed treatment zone
* History of chemical injury or delayed epithelial healing in the study eye
* Known sensitivity to study medication
* A current condition, including clinically significant dry eyes or use of medications know to induce dry eye symptoms, that, in the treating physician's opinion, would interfere with or prolong epithelial healing
* Pregnancy (including plan to become pregnant) or lactation during the course of the study

About the study

This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.

What is being tested

• Riboflavin 0.1% ophthalmic solution and pulsed light (combination product)
• Riboflavin 0.1% ophthalmic solution and non-pulsed light (combination product)

Sponsor: Price Vision Group · Participants: 500 · Started: Oct 1, 2025

Contact the study team

• Marianne Price, PhD · Phone: 317-814-2990
• Francis Price, MD · Phone: 317-814-2823

Official record on ClinicalTrials.gov — NCT07841470

Locations in the U.S.

Conditions

• Keratoconus

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.